Our Drug Pricing and Market Access team tracks recent developments in healthcare reform, the Medicaid Drug Rebate Program, the 340B Program, Medicare, and state law....more
On August 13, 2025, President Trump signed an executive order aimed at strengthening America’s pharmaceutical supply chains. Officially titled “Ensuring American Pharmaceutical Supply Chain Resilience by Filling the Strategic...more
In follow-up to the May 12th “Delivering Most Favored Nation Prescription Drug Pricing to American Patients” Executive Order, President Trump issued letters to seventeen manufacturers (Letters), reiterating the mandate for...more
Some commentators are expecting that further details regarding the so-called most favored nation (MFN) pricing policy will be released in the coming days, while other sources indicate that no further information beyond a...more
The Department of Health and Human Services (HHS) issued an interim final rule with comment period on November 27, 2020, that attempted to initiate a new drug-pricing methodology on separately-payable Medicare Part B drugs...more
A number of business certainties that we had grown accustomed-to during our adult-lives are being shaken. In addition to monitoring variables such as production-costs and import duties, international trade regulations are...more
Globalization and the need to efficiently deploy corporate resources have led many multinational companies to establish global supply networks. Although these efforts often lead to the efficient deployment of capital,...more
United States Holds First Round Of Negotiations With 13 Trading Partners Toward An Environmental Goods Agreement - On July 8, 2014, the United States and 13 other Members of the World Trade Organization (WTO),...more